Cellectis (LTS:0WA2) Margin of Safety % (DCF Earnings Based): N/A (As of Aug. 01, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0WA2 Cellectis SA LTS:0WA2
60 GF Score
Price €2.48
GF Value €2.91
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Cellectis Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Cellectis's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

LTS:0WA2 vs VRTX, REGN, RVMD: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Cellectis's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cellectis Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellectis's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Cellectis's Margin of Safety % (DCF Earnings Based) falls into.


LTS:0WA2
60GF Score
Cellectis SA LTS:0WA2
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cellectis (LTS:0WA2) Overvalued in 2026?

Based on GuruFocus' analysis, Cellectis stock appears to be undervalued. The current stock price of €2.48 is trading 14.7% below its estimated GF Value™ of €2.91. GuruFocus considers Cellectis to be Modestly Undervalued.

Key valuation signals for LTS:0WA2:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €2.91 vs. price of €2.48 (14.7% below fair value)
  • GF Score™: 60/100 with 4 warning signs

No single metric tells the full story. See the LTS:0WA2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cellectis Business Description

Address 8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
60GF Score

Get the complete analysis for LTS:0WA2

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.48
Price
€2.91
GF Value